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Abstract 
Purpose: To examine the efficacy of selected oral hypoglycaemic agent (OHA) regimens in a small 
group of patients receiving such treatment.  
Methods: This was a retrospective, observational study that involved patients who had been diagnosed 
with type 2 diabetes mellitus and undergoing routine follow-up at a teaching hospital. By reviewing 
patients’ medical records, changes in fasting blood glucose (FPG) and glycated haemoglobin (HbA1c) 
levels induced by several OHA cobmination regimens were documented. Target FPG and HbA1c were 
defined as 4.4 - 6.1 mmol/L and 6.5 %, respectively.  
Results: Based on the medical records of 156 patients reviewed, the combination of metformin and 
gliclazide was the most commonly prescribed regimen (63.46 %). The use of gliclazide + rosiglitazone + 
acarbose produced the greatest reduction in FPG and HbA1c (-4.80 mmol/L and - 4.20 %, respectively), 
but the number of patients receiving this combination was too small to allow definitive conclusions to be 
made. More patients in the triple OHA group were able to achieve the desired glycaemic control than 
those in the dual OHA group (FPG, 44.44 % versus 41.18 %; HbA1c, 52.94 % versus 47.06 %), 
highlighting the important benefits conferred by the use of multiple OHAs.  
Conclusion: The efficacy of various OHA combinations varies, and adding a third drug to a dual-agent 
regimen further reduces FPG and HbA1c levels. Though gliclazide + rosiglitazone + acarbose produces 
the greatest reduction in FPG and HbA1c levels, larger studies are required to confirm these findings.   
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Oral hypoglycaemic agents (OHAs) represent an 
important treatment option for type 2 diabetes 
mellitus (DM). Several classes of OHAs are 
available, namely thiazolidinediones (TZDs), 
insulin secretagogues [sulphonylureas (SUs) and 
non-SUs], biguanides and α-glucosidase 
inhibitors. Each of the OHA classes exerts its 
hypoglycaemic effect via a different mode of 
action. When used alone, metformin, second-
generation SUs and TZDs were found to be 
comparable with respect to their efficacy in 
reducing the glycated haemoglobin (HbA1c) 
levels [1]. 
 
The major limitation of OHA monotherapy is a 
loss of effectiveness over time, necessitating 
addition of another OHA or switch to insulin 
therapy [2]. Where the first OHA at maximum 
dosage does not achieve the desired glycaemic 
control, a second OHA from a different class is 
usually added. The most common combination 
regimens are a SU plus metformin, a SU plus a 
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TZD (for metformin-intolerant patients), or 
metformin plus a TZD (for patients with 
peripheral insulin resistance). When taken in 
combination, OHAs produce additive therapeutic 
effects by simultaneously targeting different 
glucose utilisation pathways in vivo [3, 4]. 
Combination OHA therapy is also preferable over 
insulin, the use of which is often complicated by 
compliance issues [4]. Recognising the 
indispensable role of combined OHAs in type 2 
DM, we set out to assess the efficacy of different 
OHA combination regimens in a small group of 






The study was retrospective and observational in 
design and was conducted from February 2010 
to September 2010, involving patients who had 
been diagnosed with type 2 DM and undergoing 
routine follow-up at the Endocrine Clinic, Hospital 
Universiti Kebangsaan Malaysia. Study subjects 
were identified from the electronic documentation 
system at the hospital pharmacy, according to 
the following inclusion criteria: the subject must 
be diagnosed with type 2 DM, aged at least 18 
years, and were being treated with OHAs; those 
who were prescribed with insulin or were 
pregnant, or whose medical records were 
incomplete were excluded. At the time of study 
implementation, no ethical approval was required 
as there was no direct contact with the patients; 




The following clinical data were documented 
using a questionnaire designed for this study: 
patient demographics, smoking status, alcohol 
consumption history, co-morbidities, past 
medication history, OHA regimens, and 
laboratory measurements, namely fasting plasma 
glucose (FPG) and HbA1c levels. Target 
glycaemic control was defined as a FPG of 4.4-
6.1 mmol/L and a HbA1c level < 6.5 % [5]. 
Changes in FPG or HbA1c levels were 
calculated based on the values documented 




Continuous variables were presented as mean ± 
standard deviation (SD), and categorical 
variables as counts (%). Independent T-test was 
used to compare different OHA combinations by 
the achieved FPG and HbA1c levels. P < 0.05 
was considered statistically significant. All 
statistical analyses were performed using 





The medical records of a total of 156 patients, of 
whom 91 (58.33 %) were female and 65 (41.67 
%) were male, were examined in this study 
(Table 1). These patients represented an aged 
population having a long history of type 2 DM, 
with the mean disease duration and the mean 
age being 12.41 ± 6.22 years and 60.79 ± 12.73 
years, respectively. Seventy-four (47.43 %) 
subjects were of Malay descent; whereas 56 
(35.90 %) identified as Chinese and 26 (16.67 %) 
as Indian. The majority of the patients were 
overweight (63, 40.38 %) and were found to have 
multiple co-morbidities (146, 93.59 %). Low rates 
of active smoking and alchohol consumption 
were noted, with only 29 (18.59 %) subjects 
identified as smokers and 21 (13.46 %) subjects 
found to be regularly consuming alcohol. 
 
As illustrated in Figure 1, the two most common 
OHA combinations were metformin plus 
gliclazide (99, 63.46 %), and metformin, 
gliclazide plus rosiglitazone (44, 28.21 %). The 
combination of metformin, rosiglitazone plus 
acarbose was infrequent and only one patient 
(0.64 %) was prescribed with such a regimen. 
Gliclazide, rosiglitazone plus acarbose induced 
the greatest reductions in FPG and HbA1c 
levels, namely - 4.80 mmol/L and - 4.20 %, 
respectively (Figures 2 and 3); but this regimen 
was rarely prescribed [given to only two patients 
(1.28 %)]. Analysis by independent T-test 
revealed that combined gliclazide, rosiglitazone 
and acarbose was significantly better than 
metformin plus gliclazide (p = 0.043) in regards 
to FPG control; but comparison with other 
regimens was not statistically significant. 
Similarly, gliclazide, rosiglitazone plus acarbose 
was found to produce significantly greater 
reductions in HbA1c levels when compared with 
metformin plus gliclazide, metformin, gliclazide 
plus rosiglitazone, or metformin, gliclazide plus 
acarbose (p = 0.001, p = 0.022 and p = 0.008, 
respectively). Intriguingly, the use of metformin, 
rosiglitazone plus acarbose resulted in an FPG 
increase of 0.70 mmol/L, but a paradoxical, 
marginal HbA1c reduction of - 0.40 %. 
 
Subsequently, we determined the proportions of 
patients who achieved FPG or HbA1c target 
when receiving dual or triple OHA therapy. As 
shown in Figures 4(a) and (b), more patients in 
the triple therapy group were able to achieve 
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FPG or HbA1c target than those treated with 
dual OHA therapy (FPG, 44.44 % versus 41.18 
%; HbA1c, 52.94 % versus 47.06 %). 
 
 
Table 1: Patient demographics and medical history 
 
Demographic variable Number of patients 
(N=156) 
 (%) 
Gender    
   Male 65 41.67 
   Female 91 58.33 
Age group (mean age = 60.79 ± 12.73)   
   20-44 years 18 11.54 
   45-64 years 75 48.08 
   ≥ 65 years   63 40.38 
Race   
   Malay 74 47.43 
   Chinese 56 35.90 
   Indian 26 16.67 
Body Mass Index (BMI)   
   Underweight 4 2.56 
   Normal  44 28.21 
   Overweight  63 40.38 
   Obesity  45 28.85 
Co-morbidity    
   DM + Hypertension 29 18.59 
   DM + Hyperlipidaemia 24 15.38 
   DM + Hypertension + Hyperlipidaemia 93 59.62 
   DM only 10 6.41 
Smoking   
   Yes  29 18.59 
   No  127 81.41 
Consuming alcohol   
   Yes  21 13.46 
   No  135 86.54 
Disease duration (years, mean=12.4 ± 6.2)   
1 – 5 12 7.69 
6 – 10 64 41.03 
11 – 15 46 29.49 
16 – 20 12 7.69 
21 – 25 16 10.25 
26 – 30 6 3.85 
 
 
Figure 1: Frequencies of different OHA regimens (N=156) 
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Gliclazide + rosiglitazone + acarbose versus metformin + gliclazide; p = 0.043 
Gliclazide + rosiglitazone + acarbose versus metformin + rosiglitazone; p = 0.120 
Gliclazide + rosiglitazone + acarbose versus metformin + gliclazide + rosiglitazone; p = 0.229 
Gliclazide + rosiglitazone + acarbose versus metformin + gliclazide + acarbose; p = 0.245 
 
Figure 2: Changes in FPG levels by different OHA combinations  
 
 
Gliclazide + rosiglitazone + acarbose versus metformin + gliclazide; p = 0.001 
Gliclazide + rosiglitazone + acarbose versus metformin + rosiglitazone; p=0.169 
Gliclazide + rosiglitazone + acarbose versus metformin + gliclazide + rosiglitazone; p=0.022 
Gliclazide + rosiglitazone + acarbose versus metformin + gliclazide + acarbose; p=0.008 
 




Figure 4: Proportion of patients achieving FPG (a) or HbA1c (b) target following dual or triple OHA therapy 
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In the present study, the medical records of 156 
patients who had been diagnosed with type 2 DM 
and receiving combined OHAs regimens were 
reviewed. Metformin plus gliclazide (63.46 %) 
was the most commonly prescribed regimen for 
type 2 DM, consistent with the findings of other 
studies [6,7]. Indeed, metformin is recommended 
by International Diabetes Federation as the first-
line monotherapy for type 2 DM. When the use of 
metformin alone fails to achieve 
normoglycaemia, addition of a SU is appropriate 
[8]. Combining different agents produces additive 
effects which are beneficial for certain patients 
[9]. 
 
The most frequently used triple therapy was 
metformin, gliclazide plus rosiglitazone (28.21 
%). Adding a TZD to a SU plus metformin 
conferred additional glucose-lowering benefits 
which are comparable to those of insulin use. 
Furthermore, the addition of a TZD has the 
potential to stabilize or improve beta-cell 
function, and reduce adverse cardiac risk [10, 
11]. In our study, patients who received those 
OHA combination regimens made up a major 
proportion (> 90 %) of the study population, 
showing that most physicians did adhere to 
evidence-based guidelines when prescribing 
OHAs. It is noteworthy that metformin, 
rosiglitazone plus acarbose was the least 
favoured combination, being given to only one 
patient. This is probably because concurrent 
administration of metformin and acarbose could 
lead to excessive gastrointestinal side effects 
and thus would not be tolerable [12].  
 
Overall, the mean changes in FPG and HbA1c 
values were varied and inconsistent for the OHA 
combinations examined. A decrease in FPG did 
not always translate into a corresponding HbA1c 
reduction. This is particularly true with metformin, 
rosiglitazone plus acarbose. Use of this 
combination resulted in a small increase in FPG 
of 0.70 mmol/L, but a slight decrease in HbA1c (-
0.40 %). Only one patient was prescribed with 
this combination. Therefore, it is likely that the 
discrepancy was due to patient-related factors 
such as non-compliance with the prescribed 
treatment or non-adherence to dietary 
restrictions.  
 
The use of gliclazide, rosiglitazone plus acarbose 
produced the greatest reductions in FPG and 
HbA1c values. But, statistical significance was 
not consistently attained when comparison was 
made against other drug combinations. This 
OHA combination was found to be significantly 
better than metformin plus gliclazide in reducing 
FPG; and the following regimens in reducing 
HbA1c levels: metformin plus gliclazide, 
metformin, gliclazide plus rosiglitazone, and 
metformin, gliclazide plus acarbose. However, 
because the number of patients prescribed with 
gliclazide, rosiglitazone plus acarbose is too 
small (2, 1.28 %), the statistical significance is 
dubious. Acarbose is generally considered less 
potent than other OHAs; hence, its additive effect 
to an existing dual-agent regimen should have 
been less substantial. Larger studies are 
required to confirm our findings. Until then, 
gliclazide, rosiglitazone plus acarbose cannot be 
recommended as the preferred triple OHA 
therapy.   
 
Triple OHAs were found to be better than dual-
agent regimens in regards to the proportions of 
patients achieving the target FPG and HbA1c 
levels (FPG, 44.44 % versus 41.18 %; HbA1c, 
52.94 % versus 47.06 %). Nonetheless, the 
overall glycaemic control with both treatment 
schemes was not satisfactory, with non-optimal 
treatment outcome being documented for 40-50 
% of the patients. More importantly, physicians 
seemed to refrain from prescribing triple OHAs, 
despite the fact that a substantial number of 
patients failed to achieve the desired glycaemic 
goals. This is probably due to practical 
considerations such as difficulty in adhering to a 
complex regimen. Given the progressive nature 
of type 2 DM, introducing triple-agent 
combination at lower baseline HbA1c levels 
could potentially increase the proportion of 
patients attaining and sustaining the target 
HbA1c level (7 %) [13]. The benefits conferred by 
triple therapy have been reported in other studies 
[10,13]. Triple oral antidiabetic therapy was 
proven to be an effective long-term treatment for 
patients with type 2 diabetes [14].  
 
Limitations of the study 
 
The main limitation of this study is that of sample 
size. For several OHA combinations, the number 
of patients was too small to allow definitive 
conclusions to be made. Also, the dosage of 
individual OHAs was not accounted for, and this 
might have influenced changes in FPG or 
HbA1c. The authos were also unable to examine 
patient-related confounding factors, particularly 
adherence to prescribed regimens due to the 




The combination of metformin and gliclazide is 
the most commonly prescribed OHA therapy for 
type 2 DM patients being treated at the 
Endocrine Clinic, Hospital Universiti Kebangsaan 
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Malaysia. The efficacy of different OHA 
combinations varies, and adding a third drug to a 
dual-agent regimen further reduces FPG and 
HbA1c levels. Although gliclazide + rosiglitazone 
+ acarbose produces the greatest reduction in 
FPG and HbA1c levels, larger studies are 
required to confirm these findings. Despite some 
limitations, the results of this study provide some 
clues to the design of future studies that would 
aim to assess the efficacy of dual or triple OHAs 
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